Results 31 to 40 of about 12,742 (223)

Lennox-Gastaut Syndrome: A State of the Art Review. [PDF]

, 2017
Lennox-Gastaut syndrome (LGS) is a severe age-dependent epileptic encephalopathy usually with onset between 1 and 8 years of age. Functional neuroimaging studies recently introduced the concept of Lennox-Gastaut as "secondary network epilepsy" resulting ...
Mastrangelo, Mario
core   +1 more source

Evaluations of the effect of sodium metabisulfite on the stability and dissolution rates of various model drugs from the extended release polyethylene oxide matrices [PDF]

, 2017
Purpose: This study examines the effect of sodium metabisulfite (SMB) as an antioxidant on the stability and release of various model drugs namely propranolol HCl, theophylline and zonisamide from the polyethylene oxide (PEO) tablets. The antioxidant was
Ali Nokhodchi, AR Rajabi-Siahboomi, AR Rajabi-Siahboomi, C Maderuelo, CJ Kim, CJ Kim, D Kiss, G Gallet Guillaume, GM Khan, H Lapidus, H Li, JW Moore, KA Khan, L Hongtao, L Maggi, L Maggi, L Yang, M Dimitrov, M Rane, MA Khan, Mohammed Maniruzzaman, MZ Khan, P Colombo, PI Lee, PI Lee, RC Rowe, RW Korsmeyer, S Shojaee, Saeed Shojaee, SS Davis, X Huang   +30 more
core   +1 more source

Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice

Molecules, 2022
In this research, a UHPLC–MS/MS method was developed and validated for the determination of zonisamide in dried plasma spots (DPS) and dried blood spots (DBS).
Milena Rmandić, Ana Stajić, Jasna Jančić, Janko Samardžić, Nebojša Jović, Anđelija Malenović   +5 more
doaj   +1 more source

"Electro-clinical Syndromes" with onset in Paediatric Age. the highlights of the clinical-EEG, genetic and therapeutic advances [PDF]

, 2011
The genetic causes underlying epilepsy remain largely unknown, and the impact of available genetic data on the nosology of epilepsy is still limited.
PARISI, Pasquale, Alberto Verrotti, PAOLINO, MARIA CHIARA, CASTALDO, Rosa, Filomena Ianniello, FERRETTI, ALESSANDRO, Francesco Chiarelli, VILLA, MARIA PIA   +7 more
core   +1 more source

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Cells, 2018
Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear.
Shin-Ichi Ueno, Shinji Saiki, Motoki Fujimaki, Haruka Takeshige-Amano, Taku Hatano, Genko Oyama, Kei-Ichi Ishikawa, Akihiro Yamaguchi, Shuko Nojiri, Wado Akamatsu, Nobutaka Hattori   +10 more
doaj   +1 more source

Zonisamide for the Treatment of Parkinson Disease: A Current Update

Frontiers in Neuroscience, 2020
Zonisamide has been used as an add-on treatment in order to overcome the deficiencies of the general therapies currently used to resolve the motor complications and non-motor symptoms of Parkinson disease. Various trials have been designed to investigate
Chengqian Li, Li Xue, Yumei Liu, Zhengjie Yang, Song Chi, Anmu Xie   +5 more
doaj   +1 more source

Antiepileptic drugs’ tolerability and safety – a systematic review and meta-analysis of adverse effects in dogs [PDF]

, 2016
Various anti-epileptic drugs (AEDs) are used for the management of idiopathic epilepsy (IE) in dogs. Their safety profile is an important consideration for regulatory bodies, owners and prescribing clinicians.
A Stabile, A-MOL-V Kiviranta, AA Shukralla, AE Chauvet, AK Cook, AS Nash, B Dayrell-Hart, B Mackay, C Rundfeldt, CL Gaskill, CL Gaskill, CR Hooijmans, D Moher, D Ruehlmann, D Schwartz-Porsche, D Schwartz-Porsche, David C. Brodbelt, DE Bevier, DJ Meyer, DJ Weiss, DJ Weiss, DJU Schwartz-Porsche, DM Boothe, DM Boothe, DM Conning, E Bersan, E Ernst, E Perucca, E Thrift, EM Poffenbarger, F Sturtevant, G Habock, G Jacobs, G Zaccara, G Zaccara, GC Farnbach, HA Volk, HE Baird-Heinz, Holger A. Volk, J Speciale, JA Berlin, JC Mathis, JF Summers, JG Cunningham, JH McGee, JH Rossmeisl, JK Aronson, JM Steiner, KR Dyer, L Aagaard, LAPA Nafe, LB Kantrowitz, LC Paull, LG Cuervo, LK Pearce, M Charalambous, M Govendir, M Jambroszyk, M Podell, M Raw, M Srivastava, MA Holmes, Marios Charalambous, MFD Steinberg, MH Litchfield, ML Miller, MM Aitken, N Andric, N Shaw, NA Boynosky, PA March, PB Muller, PM Henricks, PN Papanikolaou, PN Papanikolaou, R Bracchi, R Chou, RM Turner, RM Walker, S Daminet, S Derry, S Golder, S Golder, S Rieck, S Steinmetz, S Wieland, SA Kube, SA Moore, Sara K. Shivapour, SD Ross, SE Bunch, SE Bunch, SE Bunch, SE Bunch, SE Yohn, SF Foster, T Klopmann von, T Klopmann von, T Klopmann von, VJ Navarro, W Loscher, W Loscher, Y Chang, Y Heynold, YK Loke, YK Loke   +105 more
core   +3 more sources

Review: A review of the use of zonisamide in Parkinson’s disease

Therapeutic Advances in Neurological Disorders, 2009
Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding ...
Pedro Emilio Bermejo, Buenaventura Anciones   +1 more
doaj   +1 more source

Pharmacotherapies for Obesity: Past, Current, and Future Therapies [PDF]

, 2010
Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for ...
Lisa L. Ioannides-Demos, Loretta Piccenna, John J. McNeil   +2 more
core   +2 more sources

Treating patients with medically resistant epilepsy. [PDF]

, 2011
Recent evidence suggests that medically resistant epilepsy can be identified if seizures persist despite adequate doses of 2 appropriate first-line antiepileptic drugs (AEDs).
Krauss, Gregory L, Sperling, Michael R
core   +1 more source